.svg)
.svg)
Our antibodies are designed with human biology,
not around it
Our Platform
Infinimmune holds the world’s largest database of millions of paired heavy+light sequences, and countless antibody variants sourced from a continuous pipeline of diverse healthy and diseased human donors.
Hundreds of validated targets systematically mapped for specificity and functionality.
.png)
.png)
With our Complete Human sequencing technology® and Anthrobody® library-on-B-cell platform, we discover fully paired, end-to-end sequenced, antigen-specific antibody sequences from up to 300 million B cells across 350+ targets.
Using native specificity, cross-reactivity, and affinity of clonal and ultra-rare antibodies captured by the Anthrobody platform, we select optimal candidates for further development.
With our GLIMPSE™ antibody language model we combine in silico characterization and diversification with wet lab validation to optimize affinity, potency, and developability, with DC generation in as little as 8 weeks.
Benchmark development candidates in established animal models for efficacy, pharmacology, and pharmacokinetics.
Output
Our pipeline converts evolutionary successes into breakthrough medicines
Experts across immunology, AI, and drug development, working as one.
Our team combines deep immunology, AI, technology and drug development expertise to systematically mine human repertoires and bring the highest-quality antibodies into the clinic, drawing on leadership experience from teams at 10x Genomics, Pacific Biosciences, the Broad Institute, Pfizer, Amgen, Genentech, Chemocentryx, IgM Biosciences, NGM Bio, and Compugen.
Team
.png)
Clinical Advisors
Board
Investors
Stay up to date on our progress as we advance programs into the clinic and forge new partnerships.
.svg)